Today, International Stem Cell Corporation announced that it will collaborate with renowned stem cell researcher Jeanne F. Loring, Ph.D. and the Scripps Research Institute (located in La Jolla, CA) to study parthenogenetic stem cells and their potentially derived therapeutic cells. The study expands the company’s mission to generate data necessary to understand these cells and move them closer to the clinic.

ISCO has perfected a process using unfertilized human eggs to creating human stem cells. These “parthenogenetic” stem cells allow immune-matching to large segments of the population. ISCO’s process allows the company to avoid the ethical debate regarding the use of human embryos.

Company scientists have derived a type of cell found in the human eye from parthenogenetic stem cells that may have application in the treatment of macular degeneration, a common eye disease. Dr. Loring and ISCO will study these cells as part of the collaboration.

According to

...

Companies featured in this edition of the newsletter: ACTC, CVM, CHIP, ENZ, HYTM, IWEB, ONEZ, PHC, SIHI, SRCO

Markets continued their strong performance this week in the absence of any major market driving earnings or economic reports, as the broad based buying that characterized the previous week continued and led to gains in all of the major indices. All told, the Dow added 2.5% on the week, gaining 247 points to close at 10,270, up 17.0% on the year. The Nasdaq posted a 2.6% gain on the week, closing at 2,167 to extend its yearly gains to 37.5%, while the S&P 500 and Russell 2000 gained 2.3% and 1.0% respectively, bringing their yearly gains to 21.1% and 17.4%.

Equity markets carried the momentum from the previous week’s session, as the thin economic calendar and lack of significant earnings reports provided little incentive for investors to slow their buying activities.

...

Vivakor, Inc., a transdisciplinary research company that develops and acquires primarily biomedical and electro-optic products, has put together the contacts and technologies to establish a healthy position in what is estimated to be a $1.9 billion marketplace.

The company’s business model is to be a research hub focused on scientific and market needs that are not currently being met. Vivakor’s mission is to advance or acquire technologies that help patients, researchers, clinicians, and consumers, and the company realizes the importance of obtaining and coordinating the best scientific and business support to do this. To this end, it has established key relationships with various collaborative partners, and has developed strong product-specific commercialization strategies. Vivakor will have the necessary partnerships and licensing arrangements in place for each of its products from the very beginning of product conception or acquisition.

This approach has important advantages:

• More efficient research and development • Quicker time to market

...

Osiris Therapeutics (OSIR) reported a net loss of 21 cents per share in the third quarter of 2009, well above the Zacks Consensus Estimate of a net income of 6 cents. However, net loss in the year ago period was higher at 63 cents, mainly due to lower revenues.  Revenues in the reported quarter increased to $10.6 million compared to $0.995 million for the same period of the prior year. Osiris generates revenues from collaborative agreements, research licenses, and government contracts.  Revenues in the reported quarter included the recognition of $10 million in revenue under the company’s agreement with Genzyme Corporation (GENZ) for the development and commercialization of Prochymal and Chondrogen.  Osiris earned $0.4 million from its collaborative agreement with the Juvenile Diabetes Research Foundation (JDRF) for the development of Prochymal for type I diabetes, $0.1 million from its contract with the Department of ...

Companies featured in this edition of the newsletter: ACTC, CHIP, CVM, DKAM, ENZ, IWEB, MBCI, MFGD, PHC

Markets rebounded last week, on the strength of upbeat productivity and manufacturing reports that led to solid gains in all of the major indices. Despite news that the unemployment rate had hit its highest levels in 25 years, the Dow managed to end the week up 310 points, gaining 3.2% on the week to close at 10,023, up 14.2% on the year. The Nasdaq posted a gain of 3.3%, closing at 2112 and extending its yearly gains to 34%, while the S&P 500 and Russell 2000 advanced 3.2% and 3.1% respectively on the week to bring their YTD performance to 18.4% and 16.2%.

Several better than expected economic reports provided buying incentive throughout much of the week, as investors managed to shake off the previous week’s negative bias to send indices into positive territory

...

Today, BrainStorm Cell Therapeutics Inc. took the opportunity to announce that the company’s therapeutic treatment for neurodegenerative diseases displayed superior results to other current potential stem cell treatments in a recently conducted study.

The Israel Medical Association Journal published a scientific paper, authored by Ofer Sadan, Eldad Melamed and Daniel Offen from Tel Aviv University, showing the migratory capacity of Neurotrophic Factor Stem Cells (NTF-SC) in animal models of Parkinson’s and Huntington diseases. The study demonstrated that in a rat model for Parkinson’s disease, the efficacy of NTF-SC was superior in behavior, biochemical and histological indices to that of mesenchymal stem cells. The complete study and scientific paper are available on Brainstorm’s website at http://www.brainstorm-cell.com/_Uploads/47Sadan2009.pdf.

Professor Daniel Offen, Brainstorm’s chief scientific advisor, commented, “The results of this study show that the NTF-SC based treatment is efficacious due to NTF secretion and the stem cell’s migratory capabilities. Since our novel technology

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Wednesday October 28, 2009

DrStockPick.com Stock Report!

PWRM, STEM

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase II clinical

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday October 19, 2009

DrStockPick.com Stock Report!

AMLN, PWRM, MMM, CSRH, MYL, CVAT, STEM, AQNM

**************************************************************

AMLN, Amylin Pharmaceuticals, Inc.

AMLN is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines.

AMLN will webcast its Quarterly Update Conference Call for the third quarter of 2009 on Tuesday, October 20, 2009 at 5:00 p.m. ET/2:00 p.m. PT. Daniel M. Bradbury, Amylin’s president and chief executive officer, will lead the call. On the same date post-market, Amylin will release financial results for the third quarter of 2009.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a

...

For Immediate Release

Chicago, IL – October 19, 2009 – Zacks Equity Research highlights Cytori Therapeutics (CYTX) as the Bull of the Day and Red Robin Gourmet Burgers Inc. (RRGB) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Ford (F), Eaton (ETN) and TRW Automotive (TRW).

Full analysis of all these stocks is available at http://at.zacks.com/?id=2676

Here is a synopsis of all five stocks:

Bull of the Day:

We continue to be very positive on Cytori Therapeutics (CYTX) and believe the company's Celution System, a better mousetrap for quickly and efficiently harvesting adult stem cells, will see sales ramp significantly over the next few years.

Sales of the system have been tracking with our expectations. Ultimately, the clinical data will determine the pace at which the ramp continues. So far, the clinical data has been exciting,

...

Companies featured in this edition of the newsletter: ACTC, CHIP, CUR, CVM, ENZ, IMUC, IWEB, SRCO, SVUL, XSNX

Markets finally snapped their winning streak last week, as weakness in housing markets and durable goods orders led to broad-based declines in all of the major indices. All told, the Dow surrendered 155 points on the week to close at 9665, down 1.6% on the week but up 10.1% on the year. The Nasdaq lost 2.0% on the week to close at 2090, up 32.6% on the year, while the S&P 500 and Russell 2000 posted losses of 2.2% and 3.1% respectively, paring their yearly gains to 15.6% and 19.9%.

Unexpectedly poor data from the housing sector was the big economic story on the week as both new and existing August home sales failed to live up to expectations. New home sales increased modestly to 429,000, falling short of estimates calling

...